Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients
Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clu...
Saved in:
Published in | Stem cell research & therapy Vol. 14; no. 1; pp. 1 - 15 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
07.09.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. Keywords: Non-small cell lung cancer, Cancer stem cell, Stemness index, Consensus clustering, Immunotherapy, Machine learning |
---|---|
AbstractList | This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. Keywords: Non-small cell lung cancer, Cancer stem cell, Stemness index, Consensus clustering, Immunotherapy, Machine learning Abstract Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. AimThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).MethodsBased on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.ResultsPatients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.ConclusionThis new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).AIMThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.METHODSBased on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.RESULTSPatients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.CONCLUSIONThis new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. |
ArticleNumber | 238 |
Audience | Academic |
Author | Yang, Zhuofan Liu, Mingshan Zou, Wei jiang, Lei Li, Quanjin Chen, Zhiguo Zhou, Ruihao Zhang, Jingtao |
Author_xml | – sequence: 1 givenname: Mingshan surname: Liu fullname: Liu, Mingshan – sequence: 2 givenname: Ruihao surname: Zhou fullname: Zhou, Ruihao – sequence: 3 givenname: Wei surname: Zou fullname: Zou, Wei – sequence: 4 givenname: Zhuofan surname: Yang fullname: Yang, Zhuofan – sequence: 5 givenname: Quanjin surname: Li fullname: Li, Quanjin – sequence: 6 givenname: Zhiguo surname: Chen fullname: Chen, Zhiguo – sequence: 7 givenname: Lei surname: jiang fullname: jiang, Lei – sequence: 8 givenname: Jingtao surname: Zhang fullname: Zhang, Jingtao |
BookMark | eNp9k21r1TAUx4tM3Jz7Ar4KCKKwzjRJk_bVGMOHCxPBh9chTU_bjDapSareb-bHM_feDe8dYgttOf39_-eBnKfZkXUWsux5gS-KouJvQkFJJXJMaI4pwzxnj7KTQpQi52VBjva-j7OzEG5xuijFmLMn2TEVXDCCyUn2-6PSg7GARlDeGtvnpgUbTWegRSHCZCEE1IGKi4eAlG2RdjZEv-i4R-QeRrUNLE1cz4B-mjig2bveumDCOdIDTC4O4NW8Pt_amGla7H0IJfM5-aYUnfMo9ZqHSY0j0pAe42J7pJXV4NGsokkFhmfZ406NAc7u3qfZt3dvv15_yG8-vV9dX93kmmMe87asgWpdC1o3XcfbmuGybLqW4gKD4FXDStEUijCFCXRQY81arLSucNVQTgQ9zVY739apWzl7Mym_lk4ZuQ0430vlo9EjSE4Yx0CampWE6ZqqSnUNbrloNaOMVsnrcuc1L80ErU59eDUemB7-sWaQvfshC8wqKiqeHF7dOXj3fYEQ5WTCZkbKgluCJBUnRV3jcpPsxQP01i3eplltqDL1XRXkL9Wr1IGxnUuJ9cZUXglORaqb1Ym6-AeV7hYmk84DdCbFDwSvDwSJifAr9moJQa6-fD5kX-6xA6gxDsGNSzTpQByC1Q7U3oXgoZPaRLXBUjVmTFOSm9WQu9WQaTXkdjUkS1LyQHo_9P-I_gDT7hPP |
CitedBy_id | crossref_primary_10_2174_0109298673278775231101064235 crossref_primary_10_1002_imo2_14 crossref_primary_10_1111_cas_16384 |
Cites_doi | 10.1016/j.jtho.2019.07.031 10.21037/tlcr.2017.08.08 10.1016/j.cell.2017.10.049 10.1016/j.jtho.2015.09.009 10.1126/scitranslmed.3005723 10.1002/sim.3148 10.1038/nature12930 10.1172/JCI41004 10.1158/1541-7786.MCR-05-0104 10.1038/s41598-018-30525-3 10.1093/nar/gkw1092 10.1093/bib/bbx124 10.2147/CMAR.S232632 10.6004/jnccn.2022.0025 10.1093/nar/gkx356 10.1504/IJDMB.2014.064889 10.3322/caac.21262 10.3389/fgene.2019.01077 10.1016/j.mam.2013.08.003 10.1097/JTO.0b013e3182037b76 10.1172/JCI90429 10.3389/fimmu.2018.03101 10.1016/j.ctrv.2012.02.013 10.4049/jimmunol.1500447 10.1016/j.cell.2018.03.034 10.1038/75556 10.1093/bioinformatics/btq170 10.1038/s41586-019-1032-7 10.1200/JCO.2014.59.4358 10.1371/journal.pcbi.1004790 10.3322/caac.21442 10.1158/1535-7163.MCT-09-1077 10.1038/s41591-018-0136-1 10.1186/1471-2105-14-7 10.1186/s12935-018-0641-9 10.1038/ncomms11914 10.1016/B978-0-12-416022-4.00008-1 10.1001/jamanetworkopen.2019.6879 10.1164/rccm.201207-1180OC 10.1016/j.bcp.2013.04.003 10.1186/s12885-018-4389-3 10.1038/ncomms3612 10.1038/nm0901-1028 10.1016/j.cell.2013.10.029 10.7150/jca.20821 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023. BioMed Central Ltd., part of Springer Nature. BioMed Central Ltd., part of Springer Nature 2023 |
Copyright_xml | – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023. BioMed Central Ltd., part of Springer Nature. – notice: BioMed Central Ltd., part of Springer Nature 2023 |
DBID | AAYXX CITATION ISR 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13287-023-03406-4 |
DatabaseName | CrossRef Gale In Context: Science ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1757-6512 |
EndPage | 15 |
ExternalDocumentID | oai_doaj_org_article_62460e2b94524c93a8afb0d67dc43438 PMC10483786 A763734349 10_1186_s13287_023_03406_4 |
GeographicLocations | Taiwan |
GeographicLocations_xml | – name: Taiwan |
GroupedDBID | --- 0R~ 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACJQM ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION DIK E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH INR ISR ITC KQ8 LK8 M1P M7P M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SBL SOJ SV3 TUS UKHRP PMFND 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c606t-d59e3cc9739bff6d94055bfd3010e768b457b1a24a02efe90c4d0acc808b36273 |
IEDL.DBID | DOA |
ISSN | 1757-6512 |
IngestDate | Wed Aug 27 01:31:24 EDT 2025 Thu Aug 21 18:36:30 EDT 2025 Tue Aug 05 11:27:30 EDT 2025 Fri Jul 25 10:23:14 EDT 2025 Tue Jun 17 22:26:23 EDT 2025 Tue Jun 10 21:20:51 EDT 2025 Fri Jun 27 06:07:32 EDT 2025 Thu May 22 21:19:58 EDT 2025 Thu Apr 24 23:10:08 EDT 2025 Tue Jul 01 02:42:19 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c606t-d59e3cc9739bff6d94055bfd3010e768b457b1a24a02efe90c4d0acc808b36273 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://doaj.org/article/62460e2b94524c93a8afb0d67dc43438 |
PMID | 37674202 |
PQID | 2865457812 |
PQPubID | 2040189 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_62460e2b94524c93a8afb0d67dc43438 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483786 proquest_miscellaneous_2862199058 proquest_journals_2865457812 gale_infotracmisc_A763734349 gale_infotracacademiconefile_A763734349 gale_incontextgauss_ISR_A763734349 gale_healthsolutions_A763734349 crossref_citationtrail_10_1186_s13287_023_03406_4 crossref_primary_10_1186_s13287_023_03406_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-09-07 |
PublicationDateYYYYMMDD | 2023-09-07 |
PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-07 day: 07 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Stem cell research & therapy |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | W Sauerbrei (3406_CR28) 2007; 26 A Subramanian (3406_CR27) 2017; 171 KT Leeman (3406_CR6) 2014; 107 A Sokolov (3406_CR19) 2016; 12 F Degenhardt (3406_CR30) 2019; 20 S Zhou (3406_CR8) 2001; 7 S Hanzelmann (3406_CR25) 2013; 14 K Yoshihara (3406_CR20) 2013; 4 MA Postow (3406_CR17) 2015; 33 G Papafotiou (3406_CR41) 2016; 7 S Singh (3406_CR35) 2014; 39 B Zhou (3406_CR42) 2018; 128 W Li (3406_CR31) 2019; 10 B Shiotani (3406_CR9) 2006; 4 P Jiang (3406_CR26) 2018; 24 C Ju (3406_CR33) 2018; 18 J Wang (3406_CR23) 2017; 45 S Rousseaux (3406_CR18) 2013; 5 CT Yeh (3406_CR39) 2012; 186 YP Hu (3406_CR38) 2013; 85 R Zhou (3406_CR34) 2020; 12 X Wu (3406_CR36) 2012; 38 RL Siegel (3406_CR2) 2018; 68 R Rosenthal (3406_CR11) 2019; 567 BJ Morrison (3406_CR14) 2018; 18 J Malhotra (3406_CR45) 2017; 6 RM Bremnes (3406_CR7) 2011; 6 TM Malta (3406_CR40) 2018; 173 FG Giancotti (3406_CR4) 2013; 155 NY Frank (3406_CR37) 2010; 120 M Szarynska (3406_CR16) 2018; 8 E Ames (3406_CR15) 2015; 195 M Kanehisa (3406_CR22) 2017; 45 Y Yu (3406_CR44) 2019; 2 DS Ettinger (3406_CR3) 2022; 20 C Zhang (3406_CR12) 2019; 14 JZ Tang (3406_CR43) 2010; 9 TJ Desai (3406_CR5) 2014; 507 M Ashburner (3406_CR21) 2000; 25 B Stankovic (3406_CR10) 2018; 9 S Kim (3406_CR29) 2014; 10 MD Wilkerson (3406_CR24) 2010; 26 LA Torre (3406_CR1) 2015; 65 X Zhang (3406_CR13) 2018; 9 P Goldstraw (3406_CR32) 2016; 11 |
References_xml | – volume: 14 start-page: 1912 issue: 11 year: 2019 ident: 3406_CR12 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.07.031 – volume: 6 start-page: 612 issue: 5 year: 2017 ident: 3406_CR45 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2017.08.08 – volume: 171 start-page: 1437 issue: 6 year: 2017 ident: 3406_CR27 publication-title: Cell doi: 10.1016/j.cell.2017.10.049 – volume: 11 start-page: 39 issue: 1 year: 2016 ident: 3406_CR32 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.09.009 – volume: 5 start-page: 186ra166 issue: 186 year: 2013 ident: 3406_CR18 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3005723 – volume: 26 start-page: 5512 issue: 30 year: 2007 ident: 3406_CR28 publication-title: Stat Med doi: 10.1002/sim.3148 – volume: 507 start-page: 190 issue: 7491 year: 2014 ident: 3406_CR5 publication-title: Nature doi: 10.1038/nature12930 – volume: 120 start-page: 41 issue: 1 year: 2010 ident: 3406_CR37 publication-title: J Clin Invest doi: 10.1172/JCI41004 – volume: 4 start-page: 125 issue: 2 year: 2006 ident: 3406_CR9 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-05-0104 – volume: 8 start-page: 12042 issue: 1 year: 2018 ident: 3406_CR16 publication-title: Sci Rep doi: 10.1038/s41598-018-30525-3 – volume: 45 start-page: D353 issue: D1 year: 2017 ident: 3406_CR22 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw1092 – volume: 20 start-page: 492 issue: 2 year: 2019 ident: 3406_CR30 publication-title: Brief Bioinform doi: 10.1093/bib/bbx124 – volume: 12 start-page: 531 year: 2020 ident: 3406_CR34 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S232632 – volume: 20 start-page: 497 issue: 5 year: 2022 ident: 3406_CR3 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2022.0025 – volume: 45 start-page: W130 issue: W1 year: 2017 ident: 3406_CR23 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkx356 – volume: 10 start-page: 374 issue: 4 year: 2014 ident: 3406_CR29 publication-title: Int J Data Min Bioinform doi: 10.1504/IJDMB.2014.064889 – volume: 65 start-page: 87 issue: 2 year: 2015 ident: 3406_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 – volume: 10 start-page: 1077 year: 2019 ident: 3406_CR31 publication-title: Front Genet doi: 10.3389/fgene.2019.01077 – volume: 39 start-page: 50 year: 2014 ident: 3406_CR35 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2013.08.003 – volume: 6 start-page: 824 issue: 4 year: 2011 ident: 3406_CR7 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3182037b76 – volume: 128 start-page: 970 issue: 3 year: 2018 ident: 3406_CR42 publication-title: J Clin Invest doi: 10.1172/JCI90429 – volume: 9 start-page: 3101 year: 2018 ident: 3406_CR10 publication-title: Front Immunol doi: 10.3389/fimmu.2018.03101 – volume: 38 start-page: 580 issue: 6 year: 2012 ident: 3406_CR36 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2012.02.013 – volume: 195 start-page: 4010 issue: 8 year: 2015 ident: 3406_CR15 publication-title: J Immunol doi: 10.4049/jimmunol.1500447 – volume: 173 start-page: 338 issue: 2 year: 2018 ident: 3406_CR40 publication-title: Cell doi: 10.1016/j.cell.2018.03.034 – volume: 25 start-page: 25 issue: 1 year: 2000 ident: 3406_CR21 publication-title: Gene Ontol Consort Nat Genet doi: 10.1038/75556 – volume: 26 start-page: 1572 issue: 12 year: 2010 ident: 3406_CR24 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq170 – volume: 567 start-page: 479 issue: 7749 year: 2019 ident: 3406_CR11 publication-title: Nature doi: 10.1038/s41586-019-1032-7 – volume: 33 start-page: 1974 issue: 17 year: 2015 ident: 3406_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.59.4358 – volume: 12 start-page: e1004790 issue: 3 year: 2016 ident: 3406_CR19 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1004790 – volume: 68 start-page: 7 issue: 1 year: 2018 ident: 3406_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.21442 – volume: 9 start-page: 1697 issue: 6 year: 2010 ident: 3406_CR43 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-09-1077 – volume: 24 start-page: 1550 issue: 10 year: 2018 ident: 3406_CR26 publication-title: Nat Med doi: 10.1038/s41591-018-0136-1 – volume: 14 start-page: 7 year: 2013 ident: 3406_CR25 publication-title: BMC Bioinform doi: 10.1186/1471-2105-14-7 – volume: 18 start-page: 141 issue: 1 year: 2018 ident: 3406_CR33 publication-title: Cancer Cell Int doi: 10.1186/s12935-018-0641-9 – volume: 7 start-page: 11914 year: 2016 ident: 3406_CR41 publication-title: Nat Commun doi: 10.1038/ncomms11914 – volume: 107 start-page: 207 year: 2014 ident: 3406_CR6 publication-title: Curr Top Dev Biol doi: 10.1016/B978-0-12-416022-4.00008-1 – volume: 2 start-page: e196879 issue: 7 year: 2019 ident: 3406_CR44 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.6879 – volume: 186 start-page: 1180 issue: 11 year: 2012 ident: 3406_CR39 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201207-1180OC – volume: 85 start-page: 1619 issue: 11 year: 2013 ident: 3406_CR38 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2013.04.003 – volume: 18 start-page: 469 issue: 1 year: 2018 ident: 3406_CR14 publication-title: BMC Cancer doi: 10.1186/s12885-018-4389-3 – volume: 4 start-page: 2612 year: 2013 ident: 3406_CR20 publication-title: Nat Commun doi: 10.1038/ncomms3612 – volume: 7 start-page: 1028 issue: 9 year: 2001 ident: 3406_CR8 publication-title: Nat Med doi: 10.1038/nm0901-1028 – volume: 155 start-page: 750 issue: 4 year: 2013 ident: 3406_CR4 publication-title: Cell doi: 10.1016/j.cell.2013.10.029 – volume: 9 start-page: 367 issue: 2 year: 2018 ident: 3406_CR13 publication-title: J Cancer doi: 10.7150/jca.20821 |
SSID | ssj0000330064 |
Score | 2.338588 |
Snippet | Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer... This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).... AimThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer... This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer... Abstract Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1 |
SubjectTerms | Algorithms Analysis B cells Cancer Cancer stem cell Cancer therapies Chemotherapy Clustering Consensus clustering Copy number Datasets Genes Genetic aspects Genomes Genomics Immune checkpoint Immunotherapy Learning algorithms Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Machine learning Medical prognosis Microenvironments Mutation Non-small cell lung cancer Non-small cell lung carcinoma Patients Radiation therapy Regression analysis Small cell lung carcinoma Stem cells Stemness index Thoracic surgery |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKi8RKGAQEgdq1UmcxD6hgqgKEhyASnuzbMferrRNyqZ76D_rz2PG8S4NSL3ak1jJjOdhz3xDyFtnwQ8tc8OcLCBAaWTOjBOOQSRWF7nLS2titsX3-vhEfJ1Vs3TgNqS0yo1OjIq67R2ekR9gBaUA8cqLD-e_GXaNwtvV1ELjNrmD0GWY0tXMmu0ZC4dgHUzuplZG1gcDBF-wq8BQMV6CLWNiYo8ibP__yvnfhMlrFuhol9xPriM9HHn9gNzy3UNyd2wmefmIXH2LeZGepkYQc7Zox1Qg31KEa0alRoOPSJ4DNV1LXZ_wY69RsFjdggNri-ezFE9qKaZxdf2wGPYpcPkslW1d7sfXLLDGZDNEV2PWLSwB_jDt-o4NZ2a5pHhFQJegW6hDSVvRBOk6PCYnR59_fTpmqS8DcxDuXLC2Ur50TjWlsiHUrQKnr7KhBV3BPYQvFvhkc1MIwwsfvOJOtNw4J7m0YC-b8gnZgdX9U0JBI3gZJK88uDWFa2SlgpeVL4MMJqiQkXzDHe0SaDn2zljqGLzIWo8c1cBRHTmqRUbeb585HyE7bqT-iEzfUiLcdhzoV3Oddq-uC1FzX1glqkI4VRppguVt3bQOK3NlRl6hyOixdnWrNPQhaO8GCITKyJtIgZAbHeb0zM16GPSXnz8mRO8SUejhK51JJRLwrxCla0K5N6EEneCm0xvZ1UknDfrvDsrI6-00Pol5dp3v15EGTJjiFXySnMj85AdNZ7rFacQlz8f2BPWzm1d_Tu4VcQNi9dwe2QE59y_As7uwL-P2_QM-MVDS priority: 102 providerName: ProQuest |
Title | Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients |
URI | https://www.proquest.com/docview/2865457812 https://www.proquest.com/docview/2862199058 https://pubmed.ncbi.nlm.nih.gov/PMC10483786 https://doaj.org/article/62460e2b94524c93a8afb0d67dc43438 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagCIkLKi8RKItBSByo1TycxD52UauCRIUWKq24WLZjtyttE9R0D_1n_XnMON7VBiS4cMnBnrw843kkM98Q8s4a8EOLTDMrcghQapExbbllEIlVeWazwuiQbXFanZzxz_NyvtXqC3PCBnjgYeEOqpxXqcuN5GXOrSy00N6kTVU3FosiQ5kv2LytYCroYAjTwdiuq2REddBD2AX7CUwUSwuwYoyPLFEA7P9TLf-eKrlle453ycPoNNLD4WEfkTuufUzuD20kb56Q2y8hI9LR2ALinC2aIQnINRSBmlGdUe8ChmdPddtQ20Xk2C0KFupacGBl8MssxW-0FBO42q5f9PsU-HsZC7Zu9sNlFlhdsh6iV0O-LdwCPGHadi3rL_VySfHnAF2CVqEWZeyKRjDX_ik5Oz76_vGExY4MzEKgc82aUrrCWlkX0nhfNRLcvdL4BrRE6iBwMbysTaZzrtPceSdTy5tUWytSYcBS1sUzsgN3d88JBV3ghBdp6cChyW0tSumdKF3hhdde-oRka-4oG-HKsWvGUoWwRVRq4KgCjqrAUcUT8mFzzs8BrOOv1FNk-oYSgbbDAIifiuKn_iV-CXmNIqOGqtWNulCHoLdrIOAyIW8DBYJttJjNc65Xfa8-fZuNiN5HIt_BW1odiyNgrRCfa0S5N6IEbWDH02vZVVEb9Qqrj4Ez4Msl5M1mGs_EDLvWdatAA8ZLpiW8khjJ_GiBxjPt4iIgkmdDY4Lqxf9Y0pfkQR62KVbX7ZEd2A3uFXh-12ZC7tbzekLuTY9Ov84mYcvDcTb98QuwZlwr |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgguiKdYKNQgEAdqNQ8n6xwQaqFVl7YrVFqpN9dx7GWlbVI2XaH9U5z5ecw4ztKA1Fuv9iRWMuNvZux5EPJG52CHxqFiWkTgoAxEyJTmmoEnlkahDuNcuWiLUbp3wr-cJqcr5FebC4NhlS0mOqAuKo1n5JuYQclBvMLo48UPhl2j8Ha1baHRiMW-WfwEl63-MPwM_H0bRbs7x5_2mO8qwDQY65esSDITa50N4iy3Ni0yMFmS3BYg6YEB4zuHVfJQRVwFkbEmCzQvAqW1CEQOaD-I4b23yCqPwZXpkdXtndHXo-WpThDHqOTb7ByRbtbg7sE-BtXIghi0J-MdDegaBfyvDv4N0byi83bvk3veWKVbjXQ9ICumfEhuN-0rF4_I70MXiWmobz0xZpOiCT4yBcUC0Qij1BpXO7SmqiyornzF2isUzOXT4MA8xxNhimfDFAPHyqqe1BsU5OrcJ4otNtxrJpjV0g7RWRPnC0uABU7LqmT1uZpOKV5K0CmgGdUo2zPqi8jWj8nJjfDsCenB6uYpoYBBRlgRJAYMqUgPRJJZIxITW2GVzWyfhC13pPZl0rFbx1Q6d0mksuGoBI5Kx1HJ--T98pmLpkjItdTbyPQlJRb4dgPVbCw9Xsg04mlgojzjScR1FiuhbB4U6aDQmAss-mQdRUY22bJLmJJboC8GQMCzPnntKLDIR4lRRGM1r2s5_HbUIXrniWwFX6mVT8qAf4V1wTqUax1KQCHdnW5lV3oUrOXfPdsnr5bT-CRG9pWmmjsaUJpZkMAniY7Md35Qd6acfHeV0MOmIUL67PrV18mdvePDA3kwHO0_J3cjtxkxd2-N9EDmzQuwKy_zl34zU3J20_jxB8wojzM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Machine+learning-identified+stemness+features+and+constructed+stemness-related+subtype+with+prognosis%2C+chemotherapy%2C+and+immunotherapy+responses+for+non-small+cell+lung+cancer+patients&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Liu%2C+Mingshan&rft.au=Zhou%2C+Ruihao&rft.au=Zou%2C+Wei&rft.au=Yang%2C+Zhuofan&rft.date=2023-09-07&rft.pub=BioMed+Central+Ltd&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-023-03406-4&rft.externalDocID=A763734349 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon |